International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 6 Issue 4 July-August 2024 Submit your research before last 3 days of August to publish your research paper in the issue of July-August.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 6 Issue 4
July-August 2024

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Paxlovid (Nirmatrelvir/ritonavir): An Innovative Method Method for Treating Covid-19?

Author(s) Prathamesh D. Wankhade, S. G. Jawarkar, Dr. Monika P. Jadhao
Country India
Abstract Nirmatrelvir Ritonavir 3-c like protease COVID-19 SARS-COV-2Despite the need for innovative, efficient treatment for the Covid Pandemic,
there is currently no curative regimen available, leaving patients to rely on supportive and general treatments. The 3C like-protease (3CLpro) and the main protease (Mpro), two SARS-COV-2 proteins, have been identified as potential targets for antiviral medications. The Mpro might be viable therapeutic target since it plays a significant role in both the pathogenesis of the virus and processing. Nirmatrelvir, an antiviral medication, prevents SARS-CoV-2 from reproducing by blocking Mpro. Another HIV protease inhibitor, ritonavir, was coupled with nirmatrelvir to develop.

Ritonavir inhibits the cytochrome P450 3A metabolizing enzyme, extending the half-life of nirmatrelvir and serving as pharmacological enhancer. Despite major modification of the SARS-COV-2 viral genome, nirmatrelvir still has strong antiviral effectiveness against contemporary coronavirus strains. However, there are still a number of open issues.

The effectiveness of nirmatrelvir and ritonavir in treating SARS-COV-2 infection, as well as their safety and potential adverse effects are discussed in this review of literature.
Field Chemistry > Pharmacy
Published In Volume 6, Issue 2, March-April 2024
Published On 2024-04-10
Cite This Paxlovid (Nirmatrelvir/ritonavir): An Innovative Method Method for Treating Covid-19? - Prathamesh D. Wankhade, S. G. Jawarkar, Dr. Monika P. Jadhao - IJFMR Volume 6, Issue 2, March-April 2024. DOI 10.36948/ijfmr.2024.v06i02.14726
DOI https://doi.org/10.36948/ijfmr.2024.v06i02.14726
Short DOI https://doi.org/gtqx3p
View / Download PDF File

Share this


E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 6 Isu 4 Cover Page Vol 6 Isu 3 Cover Page Vol 6 Isu 2

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9898-5948-55 editor@ijfmr.com